Patents Assigned to Oncothyreon Inc.
-
Patent number: 9173929Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.Type: GrantFiled: April 1, 2005Date of Patent: November 3, 2015Assignee: ONCOTHYREON INC.Inventor: B. Michael Longenecker
-
Patent number: 9119784Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.Type: GrantFiled: September 17, 2014Date of Patent: September 1, 2015Assignee: ONCOTHYREON INC.Inventor: B. Michael Longenecker
-
Patent number: 8889616Abstract: Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.Type: GrantFiled: February 23, 2012Date of Patent: November 18, 2014Assignee: Oncothyreon Inc.Inventors: Scott Peterson, Linda Pestano, Jeffrey Millard, Diana F. Hausman, Sandy Koppenol, Robert Kirkman
-
Patent number: 8871250Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.Type: GrantFiled: June 27, 2006Date of Patent: October 28, 2014Assignee: Oncothyreon Inc.Inventor: B. Michael Longenecker
-
Publication number: 20140275234Abstract: Provided herein are novel crystalline forms of Compound 1. Also provided herein are compositions and methods of uses for the crystalline forms of Compound 1.Type: ApplicationFiled: December 27, 2011Publication date: September 18, 2014Applicant: ONCOTHYREON INC.Inventors: Jeffrey Millard, Gary Christianson, Eric Charles
-
Patent number: 8552145Abstract: The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.Type: GrantFiled: May 2, 2012Date of Patent: October 8, 2013Assignee: Oncothyreon Inc.Inventors: Wladyslaw A. Budzynski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker
-
Publication number: 20130129720Abstract: Provided herein are combination therapies for the treatment of certain cancers in a subject by administering a combination of a therapeutic and a wortmannin analog to that subject.Type: ApplicationFiled: June 3, 2011Publication date: May 23, 2013Applicant: ONCOTHYREON INC.Inventors: Scott Peterson, Diana F. Hausman, Robert Kirkman
-
Publication number: 20130131156Abstract: Provided herein are certain therapeutically effective dosing regimens for treatment of cancers with wortmannin analogs.Type: ApplicationFiled: June 3, 2011Publication date: May 23, 2013Applicant: ONCOTHYREON INC.Inventors: Scott Peterson, Diana F. Hausman, Robert Kirkman
-
Patent number: 8329639Abstract: Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.Type: GrantFiled: July 19, 2012Date of Patent: December 11, 2012Assignee: Oncothyreon Inc.Inventors: Scott Peterson, Linda Pestano, Jeffrey Millard, Diana F. Hausman, Sandy Koppenol, Robert Kirkman
-
Publication number: 20120282329Abstract: Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.Type: ApplicationFiled: July 19, 2012Publication date: November 8, 2012Applicant: Oncothyreon Inc.Inventors: Scott PETERSON, Linda Pestano, Jeffrey Millard, Diana F. Hausman, Sandy Koppenol, Robert Kirkman
-
Publication number: 20120219617Abstract: Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.Type: ApplicationFiled: February 23, 2012Publication date: August 30, 2012Applicant: Oncothyreon Inc.Inventors: Scott PETERSON, Linda Pestano, Jeffrey Millard, Diana F. Hausman, Sandy Koppenol, Robert Kirkman
-
Patent number: 8198400Abstract: The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.Type: GrantFiled: March 27, 2002Date of Patent: June 12, 2012Assignee: Oncothyreon, Inc.Inventors: Wladyslaw A. Budzynski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker
-
Publication number: 20120034294Abstract: Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate of the stream of organic solvent, and the rate of cooling of said mixture, being controlled so as to obtain a preparation of liposomes such that at least about 90% of the liposomes are of a particle size less than about 200 nm.Type: ApplicationFiled: December 17, 2009Publication date: February 9, 2012Applicant: ONCOTHYREON, INC.Inventors: Robert A. Dupuit, William J. Reilley
-
Patent number: 8097593Abstract: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.Type: GrantFiled: June 30, 2010Date of Patent: January 17, 2012Assignee: Oncothyreon Inc.Inventors: Zi-Hua Jiang, R. Rao Koganty, Wladyslaw Budzynski
-
Publication number: 20120003295Abstract: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.Type: ApplicationFiled: June 30, 2010Publication date: January 5, 2012Applicant: ONCOTHYREON INC.Inventors: Zi-Hua Jiang, R. Rao Koganty, Wladyslaw Budzynski
-
Patent number: 7820627Abstract: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.Type: GrantFiled: May 9, 2003Date of Patent: October 26, 2010Assignee: Oncothyreon Inc.Inventors: Zi-Hua Jiang, R. Rao Koganty, Wladyslaw Budzynski
-
Patent number: 7741297Abstract: Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.Type: GrantFiled: February 4, 2003Date of Patent: June 22, 2010Assignee: Oncothyreon Inc.Inventors: Zi-Hua Jiang, Rao Koganty, Damayanthi Yalamati, Myung-Gi Baek